Skip to main content

Articles By Janet Pope, MD, MPH, FRCPC

yes, no, maybe

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

By Janet Pope, MD, MPH, FRCPC
17 June 2021

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.

Read Article
light-bulbs-1125016_640.jpg

Lessons learned in SLE

By Janet Pope, MD, MPH, FRCPC
08 June 2021

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).

Read Article
Telemedicine.MD.Computer.phone (keep)

How are RA patients doing using telemedicine/virtual care?

By Janet Pope, MD, MPH, FRCPC
02 December 2020

Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?

Read Article
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

By Janet Pope, MD, MPH, FRCPC
23 November 2020

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
chain-2364830_640.jpg

Link Between Obstructive Lung Disease and Developing RA?

By Janet Pope, MD, MPH, FRCPC
09 December 2019

We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.

Read Article
Screen%20Shot%202019-06-12%20at%204.26.31%20PM.png

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

By Janet Pope, MD, MPH, FRCPC
05 July 2019

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

Read Article
eye%20exa.jpg (keep)

Blinded by the Use of Antimalarials in Lupus?

By Janet Pope, MD, MPH, FRCPC
01 July 2019

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR gui

Read Article
eye%20exa.jpg (keep)

Blinded by the Use of Antimalarials in Lupus?

By Janet Pope, MD, MPH, FRCPC
17 June 2019

Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD.

Read Article
blood%20test.jpg

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

By Janet Pope, MD, MPH, FRCPC
17 June 2018

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

Read Article
×